Netherlands Diabetes Devices Market: A Practical Healthcare Story with Strong Commercial Potential
The Netherlands diabetes devices market is moving from a support-driven healthcare category into a more dynamic, technology-led segment of modern chronic disease management. The country’s healthcare system has long emphasized early diagnosis, preventive care, and consistent monitoring, and that approach is now translating into stronger adoption of blood glucose meters, continuous glucose monitoring systems, insulin pumps, insulin pens, and connected digital tools. According to Renub Research, the market is projected to grow from US$ 392.4 billion in 2025 to US$ 737.3 billion by 2034, registering a 7.27% CAGR during 2026–2034.
At first glance, the number may look striking, but the underlying message is even more important: diabetes care in the Netherlands is becoming more proactive, more personalized, and more dependent on devices that help patients manage their condition outside the hospital. That shift is not just about convenience. It is about better outcomes, fewer complications, and stronger day-to-day control for people living with diabetes. In a healthcare environment that values prevention, this market has the right conditions for steady expansion.
Why the Market Is Expanding
A major force behind growth is the rising number of diabetes cases in the Netherlands. The market report notes that there are an estimated 1.2 million people with diabetes in the country, and around 10% of them have type 1 diabetes. As the diabetic population expands, the demand for reliable monitoring and insulin-delivery tools grows with it. Devices are no longer treated as optional add-ons; they are becoming part of routine disease management for a large share of patients.
The Dutch healthcare model also supports this growth through a strong preventive-care culture. Patients are encouraged to self-monitor and take an active role in controlling blood glucose levels. That means devices such as SMBG kits, CGMs, insulin pens, and insulin pumps are not only being prescribed more often, but also being used more consistently over time. In practical terms, this creates a market that benefits from repeat demand, regular replacement of consumables, and long-term patient dependence on monitoring technologies.
Another important factor is technology acceptance. The Netherlands has high comfort with digital healthcare tools, and that openness is helping smart glucose-management products gain ground. Patients and clinicians increasingly value real-time data, mobile app connectivity, and automated alerts that can support better therapy decisions. Smart insulin pens and app-linked glucose systems fit neatly into this environment because they give users more information without adding complexity to clinical workflows.
Preventive and Self-Managed Care Is Reshaping Daily Diabetes Management
One of the most notable themes in the Netherlands market is the move toward self-managed care. Rather than relying solely on clinic visits, patients are increasingly expected to observe glucose patterns themselves and make informed adjustments to lifestyle and treatment routines. This is where diabetes devices play a central role. Blood glucose meters, CGMs, and insulin pens are not just products; they are tools that help people participate more directly in their own care.
This shift has a powerful commercial effect as well. Self-managed care typically leads to ongoing use of consumables such as test strips, lancets, sensors, and insulin delivery accessories. It also encourages routine engagement with device ecosystems, making the market more resilient than one-time equipment categories. In other words, diabetes devices in the Netherlands are supported by both medical need and behavior change, which gives the sector a durable growth base.
The country’s broader healthcare mindset also matters. When prevention is prioritized, detection tends to happen earlier, follow-up tends to be more regular, and disease progression can often be managed more effectively. That creates a natural environment for device adoption, especially for patients who want to reduce complications and stay within target glucose ranges.
Digital Healthcare Acceptance Gives the Market an Extra Push
The Dutch market stands out because patients and professionals are increasingly comfortable with digital monitoring. That openness is helping accelerate demand for connected diabetes technologies such as smart glucose systems and software-integrated devices. Real-time information supports better decision-making, and it also allows clinicians to monitor patterns more efficiently. For many users, this is a meaningful improvement over traditional, manual tracking methods.
The report highlights the launch of Dexcom ONE+ in Europe in February 2024, a customizable real-time continuous glucose monitoring system that can be worn on different body parts. Developments like this reflect the broader direction of the market: greater convenience, more personalization, and more flexible usage. As digital healthcare infrastructure becomes more mature, demand for technically advanced monitoring systems is expected to remain strong.
The same trend is also visible in the growing use of app-friendly diabetes tools. Patients want devices that provide instant readings, send alerts, and integrate smoothly with smartphones or m-health platforms. Healthcare providers, in turn, benefit from improved data visibility and more informed therapy optimization. This creates a feedback loop that supports further adoption.
Reimbursement and Access Are Helping Adoption
A supportive reimbursement environment is another important reason the market is growing. In the Netherlands, patients have relatively good access to advanced diabetes devices, which lowers the financial barrier to adoption. This is especially significant for CGMs and insulin pumps, both of which can involve recurring costs that might otherwise limit use.
When reimbursement is consistent, patients are more likely to stay committed to long-term device use. That matters because diabetes care is not a short-term intervention. It is a lifelong routine for many people, and continuity is essential. The easier it is for patients to obtain devices and replacement consumables, the stronger the market becomes.
The report also points to the launch of Roche’s Accu-Chek Guide system in the Dutch market in 2023, showing that international brands continue to see the Netherlands as a meaningful launch and adoption environment. That kind of product activity reinforces the market’s maturity and its attractiveness for competitive device manufacturers.
Challenges Still Shape the Market
Even with strong momentum, the Netherlands diabetes devices market is not without obstacles. The biggest challenge is cost pressure. High-tech devices such as CGMs and insulin pumps often require recurring expenses, including sensors, maintenance, and ongoing replacements. For healthcare authorities, the issue is not only availability but also cost-effectiveness at scale. This can slow widespread deployment of premium technologies even when clinical value is clear.
Another challenge is usability. Not every patient is equally comfortable with advanced technology. Older users, in particular, may struggle with setup, interpretation of data, or the ongoing management of connected systems. Concerns about wearing sensors continuously or navigating digital platforms can affect long-term compliance. As a result, education and patient support remain essential parts of market growth, not just optional add-ons.
These challenges do not weaken the market story, but they do make it more realistic. Growth is being driven by need and innovation, yet adoption still depends on affordability, ease of use, and strong support from healthcare professionals.
SMBG Remains the Stable Foundation
The self-monitoring of blood glucose, or SMBG, segment continues to hold an important place in the Dutch market. Glucometers and test strips remain essential for many people with type 1 and type 2 diabetes, especially those using insulin or managing the disease through lifestyle and oral medication. Their appeal lies in simplicity, affordability, and ease of use.
While SMBG may not be growing as fast as CGM, it remains the backbone of everyday diabetes testing for a large number of patients. Its stability is supported by clinical use, routine replacement of consumables, and broad patient familiarity. In many cases, especially among newly diagnosed or older patients, SMBG is still the first and most practical monitoring solution.
CGM Is the Most Exciting Growth Segment
Among all diabetes device categories, continuous glucose monitoring is one of the fastest-moving segments in the Netherlands. CGMs provide near real-time glucose readings, trend analysis, and alerts, giving patients a much clearer picture of how their glucose levels change throughout the day. That makes them especially valuable for people with type 1 diabetes and insulin-dependent type 2 diabetes.
The appeal of CGM goes beyond convenience. It supports tighter glycaemic control and can help reduce the risk of hypoglycaemia, which makes it attractive both clinically and commercially. Integration with smartphones and m-health platforms further strengthens its value proposition. In a country that is highly receptive to digital healthcare, CGM has become one of the most important innovations in diabetes management.
Insulin Pumps and Insulin Pens Serve Different Needs
The insulin pump segment is gaining strength because it offers precise, continuous insulin infusion. For patients who need more advanced management, pumps can provide greater flexibility than multiple daily injections. Although they are more expensive and require proper training, their clinical advantage is clear. In the Netherlands, support from healthcare professionals and patient education has helped make insulin pumps a respected high-value category.
Insulin pens, meanwhile, remain widely used because they are simple, portable, and accurate. They are particularly common among patients who are starting insulin therapy or who prefer a more familiar delivery method. Both disposable and reusable formats are available, and newer smart pens with tracking features are helping modernize this category. As a result, insulin pens continue to serve as a practical bridge between traditional insulin injection and connected diabetes care.
Diagnostics Centers and Retail Pharmacies Keep the Market Accessible
Diagnostics centers have an important role in the Dutch diabetes devices ecosystem. They are used for diagnosis, monitoring, and treatment optimization, often combining SMBG tools, professional CGM solutions, and insulin management technologies. These centers help clinicians understand glycaemic patterns and guide long-term treatment more effectively. Their importance reflects the broader preventive-care orientation of the country’s healthcare system.
Retail pharmacy outlets also act as a major distribution channel. They provide easy access to glucose meters, test strips, insulin pens, CGM sensors, and related consumables. For many patients, pharmacies are the most convenient place to refill supplies and maintain daily diabetes routines. As home-based diabetes care continues to rise, pharmacies will remain a crucial access point in the market.
Market Outlook Across Devices and Users
The market spans self-monitoring devices, continuous glucose monitoring devices, insulin pumps, consumables, and insulin pens. End users include hospitals, diagnostics centers, and homecare settings. This broad spread across device types and care environments makes the market more balanced and less dependent on a single product category.
Geographically, the report maps activity across major Dutch cities such as Amsterdam, Rotterdam, The Hague, Utrecht, Eindhoven, Groningen, Tilburg, Almere, Breda, and Nijmegen. That city-level spread suggests that diabetes device adoption is not confined to one region but is distributed across the country’s healthcare network.
The competitive landscape also includes major names such as Dexcom Inc., Medtronic, Roche, Abbott Laboratories, Eli Lilly, Terumo Corporation, and BD. Their presence signals a market shaped by innovation, strong branding, and ongoing product development. With established global players competing in the space, Dutch patients are likely to continue benefiting from more advanced and more user-friendly solutions.
Final Thoughts
The Netherlands diabetes devices market is expanding for all the right reasons: rising diabetes prevalence, a strong preventive-care culture, high digital acceptance, and supportive reimbursement structures. At the same time, the market remains grounded by practical realities such as cost pressure and the need for better patient education. That balance between opportunity and challenge makes the sector especially interesting. It is not just growing; it is evolving into a more connected, more patient-centered, and more data-driven part of healthcare.
With the market projected to reach US$ 737.3 billion by 2034 from US$ 392.4 billion in 2025, the next phase of growth will likely favor technologies that combine clinical value with everyday usability. CGM, insulin delivery systems, smart pens, and connected monitoring platforms are well positioned to benefit. For manufacturers, providers, and investors alike, the Netherlands is a market where healthcare priorities and commercial potential are moving in the same direction.